Those who have been following the gene therapy space would be familiar with Solid Bio’s IGNITE-DMD trial. Beset with safety issues, the Phase I/II study was held down by clinical holds for the better part of the last three years, while the Duchenne-focused biotech watched bigger rivals dash by toward pivotal work.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,